EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis

Vered Rosenberg iD, Howard Amital, Gabriel Chodick, Freddy Faccin, Omer Gendelman

Drugs & Aging · 2024

DOI: 10.1007/s40266-024-01136-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs & Aging, 2024. Verfasst von Vered Rosenberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Biological Products, Antirheumatic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie, Tel Aviv University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: While the variety of biologics (b) and targeted synthetic (ts) disease-modifying anti-rheumatic drugs (DMARDs) available for patients with psoriatic arthritis (PsA) has proved to be efficacious in randomized clinical trials, there is a growing importance to understand the benefits and potential drawbacks of these different therapies in real-world settings, which includes bio-experienced and older patients as well. OBJECTIVE: To evaluate the real-world adherence, drug survival, and discontinuation risk of bDMARDs and tsDMARDs among patients with PsA, comprising both younger and older patients. METHODS: A retrospective study using a computerized database. Treatment-naïve and treatment-experiencedpatients with PsA, younger and older than 60 years, who initiated treatment with bDMARDs [TNF-α inhibitors (TNF-αis), IL-17 inhibitors (IL-17is), IL-12/23 inhibitors (IL-12/23i)] or tsDMARDs (the PDE-4 inhibitor apremilast) during 2015-2018 were included. Adherence was assessed using the proportion of days covered (PDC) method. Time to discontinuation was analyzed using Kaplan-Meier estimates. Risk of discontinuation was estimated by Cox proportional hazard model. RESULTS: We identified 427 eligible patients (22.2 % were older than 60 years), utilizing 673 treatment lines. The proportion of adherent patients (PDC ≥ 0.8) was similar (62.1-66.5%) across all lines of therapy and across different biologics (70.0-72.0%), while apremilast showed the lowest, in both treatment-naïve and experienced settings (43.6% and 25.5%, respectively). The Kaplan-Meier analysis showed that in the treatment-naïve TNF-αis had higher drug survival compared with apremilast (P = 0.032). Apremilast also had the lowest drug survival in the treatment-experienced group (P < 0.0001). Kaplan-Meier analysis by age groups showed similar drug survival rates in older (≥ 60 years) and younger (age < 60 years) patients, regardless of treatment-experience status. The multivariable model showed that apremilast had increased risk for discontinuation compared with TNF-αis. CONCLUSION: Adherence, drug survival and risk for discontinuation were similar for all included bDMARDs, regardless of treatment experience status, while apremilast showed lower rates and increased risk. Adherence and discontinuation rate were similar in older and younger patients. With the variety of drug modes of action available for patients with PsA, these findings may assist caregivers in selecting the appropriate treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticBiological ProductsAntirheumatic AgentsHumansMiddle AgedMaleFemaleRetrospective StudiesAgedAdultDrug Monitoring

Substanzen

Biological ProductsAntirheumatic Agents

Autor:innen und Institutionen

  • Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Medicine 'B' and Zabludowicz Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, 52621, Ramat Gan, Israel.
  • AbbVie Inc., North Chicago, IL, USA.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. omer.g79@gmail.com.
  • Department of Medicine 'B' and Zabludowicz Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, 52621, Ramat Gan, Israel. omer.g79@gmail.com.

ORCID-Profile: Vered Rosenberg

Förderung

  • AbbVie
  • Tel Aviv University

Zitieren

APA

Rosenberg, V., Amital, H., Chodick, G., Faccin, F., & Gendelman, O. (2024). Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis. Drugs & Aging. https://doi.org/10.1007/s40266-024-01136-7

Vancouver

Rosenberg V, Amital H, Chodick G, Faccin F, Gendelman O. Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis. Drugs & Aging. 2024. doi:10.1007/s40266-024-01136-7

BibTeX
@article{Rosenberg2024,
  author = {Rosenberg, Vered and Amital, Howard and Chodick, Gabriel and Faccin, Freddy and Gendelman, Omer},
  title = {Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis},
  journal = {Drugs & Aging},
  year = {2024},
  doi = {10.1007/s40266-024-01136-7}
}
Kostenlos starten →